

Intrinseque Health Secures ISO/IEC 27001:2022 Certification, Reinforcing Global Leadership in Quality and Data Security



CERTIFICATE OF REGISTRATION

Certificate No. 770744

The Information Security, Cybersecurity and Privacy Protection —
Information Security Management Systems of

Intrinseque Health Pte. Ltd.

51 Changi Business Park Central 2, #08-08 The Signature, Singapore 486066

has been audited and found to conform to

ISO / IEC 27001:2022

for the following activities

Information Security Management System for Provision of Clinical Supply Chain Solutions

*This is in accordance with the Statement of Applicability
Version 1.0 dated 05th June 2025*

Date of Issue: 19 September 2025	Date of Expiry: 18 September 2028	Initial Certification: 19 September 2025
-------------------------------------	--------------------------------------	---

Guardian Independent Certification Pte Ltd
10 Ubi Crescent #04-24 Ubi Techpark Singapore 408564

Accredited by Member of the IAF MLA



GICG - ENABLING TRUST IN A CHANGING WORLD



Singapore, Singapore Sep 26, 2025 ([IssueWire.com](https://www.issuewire.com)) - [Intrinseque Health](#) is proud to announce that it has earned the ISO/IEC 27001:2022 certification, a globally recognized standard for information security management. This new achievement further strengthens the company's already impressive portfolio of certifications, which includes EN ISO 13485, ISO 9001, and GDPMDS, reinforcing its position as a trusted partner for clinical trial support services worldwide.

Known for its operational excellence and commitment to quality, Intrinseque Health has consistently delivered top-tier clinical supply chain solutions to pharmaceutical, biotechnology, and contract research organizations. The addition of the ISO/IEC 27001:2022 certification marks a pivotal moment, ensuring that the company's systems uphold not only high standards of quality and compliance but also safeguard sensitive information with the highest levels of security.

"Information security is no longer optional; it is an essential expectation from our clients and partners," said [Mr. Nitin Jain](#), President & CEO, Intrinseque Health. "Achieving ISO/IEC 27001:2022 certification demonstrates our proactive commitment to protecting our information assets. This reinforces the trust placed in us by global stakeholders and ensures that we continue to meet and exceed the international standards for both quality and security."

The certification process included a thorough independent audit, which assessed Intrinseque Health's governance structure, risk management processes, and security systems. The successful outcome confirms that the company has developed an integrated approach that not only prevents data breaches and reduces risks but also ensures business continuity and resilience in an ever-changing regulatory landscape.

"With our existing certifications—[EN ISO 13485](#), [ISO 9001](#), and [GDPMDS](#)—we already have a strong foundation in quality and operational excellence. ISO 27001 now enhances this foundation by implementing stringent data security and privacy standards. Together, these certifications reflect our belief that ethical responsibility, quality management, and information security are inseparable pillars of long-term success. Our clients can trust that Intrinseque Health will continue delivering services with integrity, reliability, and respect for the most critical asset of today: information," added Mr. Jain.

As the clinical research industry faces increasingly complex challenges, from regulatory compliance to data protection, Intrinseque Health's attainment of ISO/IEC 27001:2022 certification represents a key milestone that enhances its ability to support global clinical trials with confidence and credibility.

About Intrinseque Health

Intrinseque Health is an EN ISO 13485, ISO 9001, GDPMDS and now ISO 27001 certified global clinical development support organisation, accomplished in facilitating the development of clinical trial studies globally. Around the globe, Intrinseque Health has offices in countries like the United States (Delaware), The Netherlands (Amsterdam), United Kingdom (London), China (Beijing), Taiwan (Taipei) & Korea (Seoul), India (Delhi), Malaysia (Melaka) and Singapore. Being managed by drug development professionals with over 300 years of combined experience supporting global clinical trials across various therapeutic areas, the team at Intrinseque Health knows and understands the needs of the clients while providing best-in-class solutions to overcome the hurdles and pain points of conducting a

clinical trial.

Intrinseque Health is the industry expert in solving clinical supply chain challenges, such as product availability & lead times, selection of in-country sourcing Vs. import, import regulations and IOR/EOR requirements, storage & warehousing, kitting, labelling & printing, installation, calibration, validation, servicing & maintenance of equipment and supplies, local sourcing, and procurement services, all while maintaining the highest levels of quality throughout study timelines. Intrinseque Health engages early with its clients and utilises an operational methodology based on a proven, cost-effective clinical supply chain strategy for each clinical trial. It firmly believes that even the most minor and essential items, irrespective of their utility, should be there every time because nothing is more important than the value of patients' life. Intrinseque Health aims to become the global leader in clinical trial support services and constantly thrives in innovating and offering unique solutions.

Media Contact

Intrinseque Health

*****@intrinsequehealth.com

6591019015

51 Changi Business Park Central 2, #08-08 The Signature, Singapore 486066

Source : Intrinseque Health

[See on IssueWire](#)

